Purpose: To uncover the signaling pathways underlying follicular lymphoma-follicular dendritic cells (FL-FDC) cross-talk and its validation as new targets for therapy.
Experimental Design: FL primary cells and cell lines were cocultured in the presence or absence of FDC. After 24 and 48 hours, RNA was isolated from FL cells and subjected to gene expression profiling (GEP) and data meta-analysis using DAVID and GSEA softwares. Blockade of PI3K pathway by the pan-PI3K inhibitor BKM120 (buparlisib; Novartis Pharmaceutical Corporation) and the effect of PI3K inhibition on FL-FDC cross-talk were analyzed by means of ELISA, RT-PCR, human umbilical vein endothelial cell tube formation, adhesion and migration assays, Western blot, and in vivo studies in mouse FL xenografts.
Results: GEP of FL-FDC cocultures yields a marked modulation of FL transcriptome by FDC. Pathway assignment by DAVID and GSEA software uncovered an overrepresentation of genes related to angiogenesis, cell adhesion, migration, and serum-response factors. We demonstrate that the addition of the pan-PI3K inhibitor BKM120 to the cocultures was able to downregulate the expression and secretion of proangiogenic factors derived from FL-FDC cocultures, reducing in vitro and in vivo angiogenesis. Moreover, BKM120 efficiently counteracts FDC-mediated cell adhesion and impedes signaling and migration induced by the chemokine CXCL12. BKM120 inhibits both constitutive PI3K/AKT pathway and FDC- or CXCL12-induced PI3K/AKT pathway, hampers FDC survival signaling, and reduces cell proliferation of FL cells in vitro and in mouse xenografts.
Conclusions: These data support the use of BKM120 in FL therapy to counteract microenvironment-related survival signaling in FL cells.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1158/1078-0432.CCR-14-0154 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The simultaneous use of CRISPR/Cas9 to knock out the PI3Kca gene with radiation to enhance radiosensitivity and inhibit tumor growth in breast cancer.
Iran J Basic Med Sci
January 2024
Department of Medical Physics, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Objectives: Breast neoplasm is a malignancy that can have a poor prognosis. The PI3K/AKT signaling pathway is frequently activated in various tumor types, including breast cancer, leading to alterations in the tumor microenvironment and radioresistance. Selective inhibition of PI3Kca (p110α) has been considered an alternative approach to overcome radioresistance, owing to concerns surrounding the excessive side effects of pan-PI3K inhibitors tested in clinical trials.
View Article and Find Full Text PDFFunctional Assessments of Gynecologic Cancer Models Highlight Differences Between Single-Node Inhibitors of the PI3K/AKT/mTOR Pathway and a Pan-PI3K/mTOR Inhibitor, Gedatolisib.
Cancers (Basel)
October 2024
Celcuity, Inc., 16305 36th Ave N, Suite 100, Minneapolis, MN 55446, USA.
: The PI3K/AKT/mTOR (PAM) pathway is frequently activated in gynecological cancers. Many PAM inhibitors selectively target single PAM pathway nodes, which can lead to reduced efficacy and increased drug resistance. To address these limitations, multiple PAM pathway nodes may need to be inhibited.
View Article and Find Full Text PDFAssessments of prostate cancer cell functions highlight differences between a pan-PI3K/mTOR inhibitor, gedatolisib, and single-node inhibitors of the PI3K/AKT/mTOR pathway.
Mol Oncol
January 2025
Celcuity, Inc., Minneapolis, MN, USA.
Article Synopsis
- Metastatic castration-resistant prostate cancer (mCRPC) often shows loss of sensitivity to androgen receptors and activation of the PI3K/AKT/mTOR pathway, making treatment difficult due to feedback mechanisms that lead to drug resistance.
- The study suggests that gedatolisib, a potent multi-target inhibitor of the PI3K pathway and mTORC1/2, is more effective than single-node PAM inhibitors for treating prostate cancer cells, regardless of their PTEN/PIK3CA status.
- Gedatolisib's superior effectiveness arises from its ability to impact critical cell functions, and it is currently in a clinical trial combined with darolutamide for patients with mCRPC.
Antiplatelet drug ticagrelor suppresses triple negative breast cancer metastasis by targeting PI3K.
Biochem Pharmacol
August 2024
School of Pharmaceutical Science & Yunnan Key Laboratory of Pharmacology for Natural Products, Kunming Medical University, Kunming 650500, Yunnan, China; Yunnan College of Modern Biomedical Industry, Kunming Medical University, Kunming 650500, Yunnan, China. Electronic address:
Metastatic recurrence is still a major challenge in breast cancer treatment. Patients with triple negative breast cancer (TNBC) develop early recurrence and relapse more frequently. Due to the lack of specific therapeutic targets, new targeted therapies for TNBC are urgently needed.
View Article and Find Full Text PDFGedatolisib shows superior potency and efficacy versus single-node PI3K/AKT/mTOR inhibitors in breast cancer models.
NPJ Breast Cancer
June 2024
Celcuity, Inc. 16305 36th Ave N, Suite 100, Minneapolis, MN, 55446, USA.
Article Synopsis
- The PAM pathway, often disrupted in breast cancer, involves interlinked signaling that supports tumor growth, and current treatments typically target only one part of this pathway.
- Researchers propose that gedatolisib, a pan-PI3K/mTOR inhibitor, could be more effective than single-node PAM inhibitors by addressing multiple targets, potentially reducing drug resistance in breast cancer cells.
- In laboratory tests, gedatolisib showed superior anti-cancer effects compared to other PAM inhibitors by decreasing cell survival and invasive behavior across various breast cancer cell lines, leading to further clinical evaluation in a Phase 3 study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!